Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome (NCT07247162) | Clinical Trial Compass
Not Yet RecruitingPhase 4
Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome
63 participantsStarted 2026-08
Plain-language summary
Osilodrostat has proven to be a safe and efficacious treatment for patients with CS. Demonstrating normalisation of hypercortisolaemia and in patients with hypertension and/or dysglycaemia clinically relevant and statistically significant reductions in blood pressure and glycaemia. This study aims at providing additional evidence on the safety, efficacy and appropriate dosing of osilodrostat in patients with CS, who have hypertension.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Male or female ≥ 18 years of age
✓. Able to provide and have provided signed written informed consent prior to study participation
✓. Diagnosis of endogenous Cushing's Syndrome
✓. mUFC values from two 24h urinary collections \> ULN and ≤ 2x ULN
✓. Participants with uncontrolled hypertension on stable doses of BP lowering medications (for at least 4 weeks); qualifying BP measurements by ABPM taken prior to randomisation defined as: Average of 24h ABPM SBP ≥ 135 or DBP ≥ 85 mmHg
✓. Participants under glucocorticoid replacement therapy can be recruited only if this therapy has been already stopped for at least seven days or 5 half-lives prior to screening, whichever was longer
✓. Not taking any drug therapy for CS. The following minimum periods without these medications need to be completed before baseline assessments:
. Participants who are scheduled for a surgery to treat CS within 32 weeks of randomisation to the study drug
✕. Presence of a known "long term" history of both hypertension and diabetes (defined as both hypertension and diabetes diagnosed \>10 years prior to the initial diagnosis of endogenous CS)
✕. History of cyclic Cushing's Syndrome with fluctuating clinical manifestations
✕. Participants with pseudo-CS
✕. Participants with compression of the optic chiasm due to a macroadenoma or participants at high risk of compression of the optic chiasm (tumour within 2 mm of optic chiasm)